Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of IL‐17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections
Michael Kammüller, Tsen‐Fang Tsai, C.E.M. Griffiths, et al.
Clinical & Translational Immunology (2017) Vol. 6, Iss. 8
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)
Kevin Winthrop, Xavier Mariette, J.T. Silva, et al.
Clinical Microbiology and Infection (2018) Vol. 24, pp. S21-S40
Open Access | Times Cited: 224
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
Dennis McGonagle, Iain B. McInnes, Bruce Kirkham, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 9, pp. 1167-1178
Open Access | Times Cited: 207
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study
Tiago Torres, Andrea Chiricozzi, L. Puig, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 333-342
Open Access | Times Cited: 27
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Joshua S. Davis, David Ferreira, Emma Paige, et al.
Clinical Microbiology Reviews (2020) Vol. 33, Iss. 3
Open Access | Times Cited: 119
Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness
Ya‐Chu Tsai, Tsen‐Fang Tsai
Therapeutic Advances in Musculoskeletal Disease (2017) Vol. 9, Iss. 11, pp. 277-294
Open Access | Times Cited: 117
Safety of biologics in psoriasis
Masahiro Kamata, Yayoi Tada
The Journal of Dermatology (2017) Vol. 45, Iss. 3, pp. 279-286
Closed Access | Times Cited: 116
The TNF/IL‐23/IL‐17 axis—Head‐to‐head trials comparing different biologics in psoriasis treatment
Lisa Lynn ten Bergen, Aleksandra Petrović, Anders Krogh Aarebrot, et al.
Scandinavian Journal of Immunology (2020) Vol. 92, Iss. 4
Open Access | Times Cited: 97
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics
Ying‐Ming Chiu, Der‐Yuan Chen
Expert Review of Clinical Immunology (2019) Vol. 16, Iss. 2, pp. 207-228
Closed Access | Times Cited: 88
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 425-442
Open Access | Times Cited: 85
Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change
Miguel Nogueira, Richard B. Warren, Tiago Torres
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 4, pp. 824-834
Closed Access | Times Cited: 72
Recurrent NTM pulmonary disease despite avoidance of hot spring exposure in a plaque psoriasis patient treated with Secukinumab: a case report
Yixiao Wei, Chunlei Wang, Lingtao Chong, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs
Delia Goletti, Linda Petrone, Giuseppe Ippolito, et al.
Expert Review of Anti-infective Therapy (2018) Vol. 16, Iss. 6, pp. 501-512
Open Access | Times Cited: 71
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
Boni E. Elewski, John W. Baddley, Atul Deodhar, et al.
JAMA Dermatology (2020) Vol. 157, Iss. 1, pp. 43-43
Open Access | Times Cited: 64
The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond
Sayam Dubash, Charlie Bridgewood, Dennis McGonagle, et al.
Expert Review of Clinical Immunology (2018) Vol. 15, Iss. 2, pp. 123-134
Open Access | Times Cited: 60
Tuberculosis and Biologic Therapies
Mark Godfrey, Lloyd N. Friedman
Clinics in Chest Medicine (2019) Vol. 40, Iss. 4, pp. 721-739
Closed Access | Times Cited: 60
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease
Alfonso Motolese, Manuela Ceccarelli, Laura Macca, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 228-228
Open Access | Times Cited: 29
Updates on ankylosing spondylitis: pathogenesis and therapeutic agents
Se Hee Kim, Sang‐Hoon Lee
Journal of Rheumatic Diseases (2023) Vol. 30, Iss. 4, pp. 220-233
Open Access | Times Cited: 18
Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice
Fabrizio Cantini, Laura Niccoli, Alessandro Capone, et al.
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 5, pp. 415-425
Closed Access | Times Cited: 53
Risk of tuberculosis reactivation during interleukin‐17 inhibitor therapy for psoriasis: a systematic review
Emilie Fowler, Rima I. Ghamrawi, Neda Ghiam, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 7, pp. 1449-1456
Closed Access | Times Cited: 50
Ixekizumab for the treatment of psoriasis: up-to-date
Sarah Craig, Richard B. Warren
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 6, pp. 549-557
Closed Access | Times Cited: 50
Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
Peter Nash, Iain B. McInnes, Philip J. Mease, et al.
Rheumatology and Therapy (2018) Vol. 5, Iss. 1, pp. 99-122
Open Access | Times Cited: 47
TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis
Ainhoa Arbués, Dominique Brees, Salah‐Dine Chibout, et al.
PLoS Pathogens (2020) Vol. 16, Iss. 2, pp. e1008312-e1008312
Open Access | Times Cited: 41
Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
Gerasimos Evangelatos, Vasiliki Koulouri, Alexios Iliopoulos, et al.
Therapeutic Advances in Musculoskeletal Disease (2020) Vol. 12
Open Access | Times Cited: 41
New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management
J.M. Carrascosa, Elena Del-Alcazar
Expert Review of Clinical Immunology (2018) Vol. 14, Iss. 4, pp. 259-273
Closed Access | Times Cited: 40
Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis
Kerasia‐Maria Plachouri, Sophia Georgiou
Journal of Dermatological Treatment (2018) Vol. 30, Iss. 7, pp. 668-673
Closed Access | Times Cited: 39
Page 1 - Next Page

Scroll to top